Novo Nordisk ends balaglitazone development

Dr. Reddy's (RDY) said partner NVO discontinued development of balaglitazone after preclinical results showed the partial peroxisome proliferator-activated receptor (PPAR) gamma agonist did not provide a sufficient competitive advantage over similar marketed Type II diabetes products. The compound, which was licensed from RDY in 1997, had completed Phase II trials for the indication. ...